

1898

MULTIPLE BOTULINUM TOXINS FOR TREATING NEUROMUSCULAR
DISORDERS AND CONDITIONS

5 FIELD OF THE INVENTION

10 The present invention provides novel methods and
composition for treating diseases of the nervous
system, e.g., neuromuscular disorders and conditions,
with botulinum toxins. In addition, the present
invention provides methods useful in all tissue and
organ systems which involve the release of
neurotransmitters, especially acetylcholine. These
cholinergic transmission systems include neuromuscular
15 junctions (muscles), smooth muscles (gut, sphincters,
etc.) and secretions (salivation and mucus).

BACKGROUND OF THE INVENTION

20 A bacterial toxin, botulinum toxin, in particular
botulinum toxin type A, has been used in the treatment
of a number of neuromuscular disorders and conditions
involving muscular spasm; for example, strabismus,
blepharospasm, spasmodic torticollis (cervical
25 dystonia), oromandibular dystonia and spasmodic
dysphonia (laryngeal dystonia). The toxin binds
rapidly and strongly to presynaptic cholinergic nerve
terminals and inhibits the exocytosis of acetylcholine
by decreasing the frequency of acetylcholine release.
30 This results in local paralysis and hence relaxation
of the muscle afflicted by spasm.

For one example of treating neuromuscular
disorders, see U.S. Patent No. 5,053,005 to Borodic,
35 which suggests treating curvature of the juvenile

spine, i.e., scoliosis, with an acetylcholine release inhibitor, preferably botulinum toxin A.

For the treatment of strabismus with botulinum toxin type A, see Elston, J.S., et al., *British Journal of Ophthalmology*, 1985, 69, 718-724 and 891-896. For the treatment of blepharospasm with botulinum toxin type A, see Adenis, J.P., et al., *J. Fr. Ophthalmol.*, 1990, 13 (5) at pages 259-264. For treating squint, see Elston, J.S., *Eye*, 1990, 4(4):VII. For treating spasmodic and oromandibular dystonia torticollis, see Jankovic et al., *Neurology*, 1987, 37, 616-623.

Spasmodic dysphonia has been treated with botulinum toxin type A. See Blitzer et al., *Ann. Otol. Rhino. Laryngol*, 1985, 94, 591-594. Lingual dystonia was treated with botulinum toxin type A according to Brin et al., *Adv. Neurol.* (1987) 50, 599-608. Finally, Cohen et al., *Neurology* (1987) 37 (Suppl. 1), 123-4, discloses the treatment of writer's cramp with botulinum toxin type A.

The term botulinum toxin is a generic term embracing the family of toxins produced by the anaerobic bacterium *Clostridium botulinum* and, to date, seven immunologically distinct neurotoxins have been identified. These have been given the designations A, B, C, D, E, F and G. For further information concerning the properties of the various botulinum toxins, reference is made to the article by Jankovic and Brin, *The New England Journal of Medicine*, No. 17, 1990, pp. 1186-1194, and to the review by Charles L. Hatheway in Chapter 1 of the book entitled *Botulinum Neurotoxin and Tetanus Toxin*, L. L. Simpson, Ed.,

published by Academic Press Inc. of San Diego, California, 1989, the disclosures in which are incorporated herein by reference.

5 The neurotoxic component of botulinum toxin has
a molecular weight of about 150 kilodaltons and is
thought to comprise a short polypeptide chain of about
50 kD which is considered to be responsible for the
toxic properties of the toxin, i.e., by interfering
10 with the exocytosis of acetylcholine, by decreasing
the frequency of acetylcholine release, and a larger
polypeptide chain of about 100 kD which is believed to
be necessary to enable the toxin to bind to the pre-
synaptic membrane. The "short" and "long" chains are
15 linked together by means of a simple disulfid bridge.
(It is noted that certain serotypes of botulinum
toxin, e.g., type E, may exist in the form of a single
chain un-nicked protein, as opposed to a dichain. The
single chain form is less active but may be converted
20 to the corresponding dichain by nicking with a
protease, e.g., trypsin. Both the single and the
dichain are useful in the method of the present
invention.)

25 Immunotoxin conjugates of ricin and antibodies,
which are characterized as having enhanced cytotoxi-
city through improving cell surface affinity, are
disclosed in European Patent Specification 0 129 434.
The inventors note that botulinum may be utilized in
30 place of ricin.

Botulinum toxin is obtained commercially by
establishing and growing cultures of *C. botulinum* in
a fermenter and then harvesting and purifying the
35 fermented mixture in accordance with known techniques.

Botulinum toxin type A, the toxin type generally utilized in treating neuromuscular conditions, is currently available commercially from several sources; for example, from Port Products Ltd. UK, under the trade name "DYSPORT," and from Allergan, Inc., Irvine, California, under the trade name BOTOX®.

It is one object of the invention to provide novel treatments of neuromuscular disorders and conditions with botulinum toxin type A in combination with botulinum toxin types B, C, D, E, F and G.

SUMMARY OF THE INVENTION

The present invention provides a composition and a method of treating a neuromuscular disorder or condition such as strabismus and other disorders of ocular motility, e.g., comitant and vertical strabismus, lateral rectus palsy, nystagmus, dysthyroid myopathy, etc.; dystonia, e.g., focal dystonias such as spasmodic torticollis, writer's cramp, blepharospasm, oromandibular dystonia and the symptoms thereof, e.g., bruxism, Wilson's disease, tardive dystonia, laryngeal dystonia etc.; other dystonias, e.g., tremor, tics, segmental myoclonus; spasms, such as spasticity due to chronic multiple sclerosis, spasticity resulting in abnormal bladder control, e.g., in patients with spinal cord injury, animus, back spasm, charley horse etc.; tension headaches; levator pelvic syndrome; spina bifida, tardive dyskinesia; Parkinson's and limb (focal) dystonia and stuttering, etc. of a patient, which method comprises administering to the patient suffering from said disorder or condition a therapeutically effective amount of botulinum toxin

type A in combination with a neurotoxin selected from the group consisting of botulinum toxin types B, C, D, E, F and G. The clinical features of the above-listed neuromuscular disorders and conditions are described in Jankovic and Brin, cited above, and in Quinn, *Disorders of Movement*, Academic Press, 1989, all of which are incorporated herein by reference.

The present invention further provides compositions of said botulinum toxins in a vehicle suitable for injection of said toxins into the appropriate region of the patient to be treated. Alterations of the vehicle and excipient may include materials designed to retain the injected toxin in the local area.

The present invention further provides a composition and a method for treating neuromuscular disorders or conditions requiring a short duration of therapeutic action (measured in hours or days) or an intermediate duration of therapeutic action (measured in weeks). For example, a short or intermediate duration neurotoxin may be used in procedures to temporarily immobilize a joint or prevent muscle contractions prior to or after surgery or a procedure. Examples of these conditions include: total joint replacement, treatment of compound fractures, joint infections, dislocations. Other uses of a short duration of action product are to aid in joint dislocations, relaxation for physical therapy, alleviation of muscle spasms (to break the cycle of pain and spasm). In addition, a short duration therapy may be useful to determine the muscles involved in curvature of the spine in scoliosis. Unusual spasms of sphincter muscles (ocular,

gastrointestinal, vaginal, etc.) may be treated with short duration therapy.

On the other hand, an intermediate duration product may be useful in treating tendon or ligament alignment repair. If a muscle is damaged after trauma, immobilization with an intermediate may help with pain and facilitate healing. In addition, an intermediate duration therapy may be useful in determination of muscles involved in curvature of the spine in scoliosis. Unusual spasms of sphincter muscles (ocular, gastrointestinal, vaginal, etc.) may be treated with intermediate duration therapy.

DETAILED DESCRIPTION

The botulinum toxins used according to the present invention are botulinum toxins type A, B, C, D, E, F and G.

Each serotype of botulinum toxin has been identified as immunologically different proteins through the use of specific antibodies. For example, if the antibody (antitoxin) recognizes, that is, neutralizes the biological activity of, for example, type A it will not recognize types B, C, D, E, F or G.

While all of the botulinum toxins appear to be zinc endopeptidases, the mechanism of action of different serotypes, for example, A and E within the neuron appear to be different than that of type B. In addition, the neuronal surface "receptor" for the toxin appears to be different for the serotypes.

The physiologic groups of *Clostridium botulinum* types are listed in Table I.

Table I. Physiologic Groups of *Clostridium botulinum*

Group	Toxin Sero-Type	Biochemistry	Milk Digest	Glucose Fermentation	Lipase	Phages & Plasmids	Phenotypically Related Clostridium (nontoxigenic)
I	A,B,F	proteolytic saccharolytic	+	+	+	+	<u>C. sporogenes</u>
II	B,E,F	nonproteolytic saccharolytic psychotrophic	-	+	+	+	
III	C,D	nonproteolytic saccharolytic	+	+	+	+	<u>C. novyi</u>
IV	G	proteolytic nonsaccharolytic	+	-	-	-	<u>C. subterminale</u>

These toxin types may be produced by selection from the appropriate physiologic group of *Clostridium botulinum* organisms. the organisms designated as Group I are usually referred to as proteolytic and produce botulinum toxins of types A, B and F. The organisms designated as Group II are saccharolytic and produce botulinum toxins of types B, E and F. The organisms designated as Group III produce only botulinum toxin types C and D and are distinguished from organisms of Groups I and II by the production of significant amounts of propionic acid. Group IV organisms only produce neurotoxin of type G. The production of any and all of the botulinum toxin types A, B, C, D, E, F and G are described in Chapter 1 of *Botulinum Neurotoxin and Tetanus Toxin*, cited above, and/or the references cited therein. Botulinum toxins types B, C, D, E, F and G are also available from various species of clostridia. Currently fourteen species of clostridia are considered pathogenic. Most of the pathogenic strains produce toxins which are responsible for the various pathological signs and symptoms. Organisms which produce botulinum toxins have been isolated from botulism outbreaks in humans

(types A, B, E and F) and animals (types C and D). Their identities were described through the use of specific antitoxins (antibodies) developed against the earlier toxins. Type G toxin was found in soil and has low toxigenicity. However, it has been isolated from autopsy specimens, but thus far there has not been adequate evidence that type G botulism has occurred in humans.

In general, four physiologic groups of *C. botulinum* are recognized (I, II, III, IV). The organisms capable of producing a serologically distinct toxin may come from more than one physiological group. For example, Type B and F toxins can be produced by strains from Group I or II. In addition, other strains of clostridial species (*C. baratii*, type F; *C. butyricum*, type E; *C. novyi*, type C₁ or D) have been identified which can produce botulinum neurotoxins.

Preferably, the toxin is administered by means of intramuscular injection directly into a spastic muscle, in the region of the neuromuscular junction, although alternative types of administration (e.g., subcutaneous injection), which can deliver the toxin directly to the affected muscle region, may be employed where appropriate. The toxin can be presented as a sterile pyrogen-free aqueous solution or dispersion and as a sterile powder for reconstitution into a sterile solution or dispersion.

Where desired, toxicity adjusting agents such as sodium chloride, glycerol and various sugars can be added. Stabilizers such as human serum albumin may also be included. The formulation may be preserved by

means of a suitable pharmaceutically acceptable preservative such as a paraben, although preferably it is unpreserved.

5 It is preferred that the toxin is formulated in unit dosage form; for example, it can be provided as a sterile solution in a vial or as a vial or sachet containing a lyophilized powder for reconstituting a suitable vehicle such as water for injection.

10 In one embodiment, the botulinum toxin is formulated in a solution containing saline and pasteurized human serum albumin, which stabilizes the toxin and minimizes loss through non-specific adsorption. The solution is sterile filtered (0.2 micron filter), filled into individual vials and then vacuum-dried to give a sterile lyophilized powder. In use, the powder can be reconstituted by the addition of sterile unpreserved normal saline (sodium chloride
15 0.9% for injection).

20 The dose of toxin administered to the patient will depend upon the severity of the condition; e.g., the number of muscle groups requiring treatment, the age and size of the patient and the potency of the toxin. The potency of the toxin is expressed as a multiple of the LD₅₀ value for the mouse, one unit (U) of toxin being defined as being the equivalent amount of toxin that kills 50% of a group of 18 to 20 female
25 Swiss-Webster mice, weighing about 20 grams each.

30 The dosages used in human therapeutic applications are roughly proportional to the mass of muscle being injected. Typically, the dose administered to the patient may be up to about 1,000 units;
35

for example, up to about 500 units, and preferably in the range from about 80 to about 460 units per patient per treatment, although smaller or larger doses may be administered in appropriate circumstances.

5

As the physicians become more familiar with the use of this product, the dose may be changed. In the botulinum toxin type A, available from Porton, DYSPORT, 1 nanogram (ng) contains 40 U. 1 ng of the
10 botulinum toxin type A, available from Allergan, Inc., i.e., BOTOX®, contains 4 U. The potency of botulinum toxin and its long duration of action mean that doses will tend to be administered on an infrequent basis. Ultimately, however, both the quantity of toxin
15 administered and the frequency of its administration will be at the discretion of the physician responsible for the treatment and will be commensurate with questions of safety and the effects produced by the toxin.

20

The invention will now be illustrated by reference to the following nonlimiting examples.

In each of the examples, the appropriate muscles
25 of each patient are injected with a sterile solution containing the confirmation of botulinum toxin. Total patient doses range from 80 U to 460 U. Before injecting any muscle group, careful consideration is given to the anatomy of the muscle group, the aim
30 being to inject the area with the highest concentration of neuromuscular junctions, if known. Before injecting the muscle, the position of the needle in the muscle is confirmed by putting the muscle through its range of motion and observing the
35 resultant motion of the needle end. General

anaesthesia, local anaesthesia and sedation are used according to the age of the patient, the number of sites to be injected, and the particular needs of the patient. More than one injection and/or sites of
5 injection may be necessary to achieve the desired result. Also, some injections, depending on the muscle to be injected, may require the use of fine, hollow, teflon-coated needles, guided by electromyography.

10

Following injection, it is noted that there are no systemic or local side effects and none of the patients are found to develop extensive local hypotonicity. The majority of patients show an improvement
15 in function both subjectively and when measured objectively.

Example 1

The Use of Botulinum Toxin Type in the Treatment
20 of Tardive Dyskinesia

20

A patient, suffering from joint dislocation, is treated with a composition having up to 500 units of botulinum toxin type A and a lesser amount of botulinum toxin type B by direct injection of such toxin
25 into the joint. After several hours, the joint is immobilized and muscle contractions are relieved. An increase, or enhancement, of the relief of muscle enhancement caused by the combination of botulinum toxin type A and B for a short duration enables
30 immediate treatment while the long term relief of muscle enhancement enables healing of the reset joint.

Example 1(a)

5 The method of Example 1 is repeated, except that
a combination of botulinum toxin type A and B is used
with similar results.

Example 1(b)

10 The method of Example 1 is repeated, except that
a combination of botulinum toxin type A and C is used
with similar results.

Example 1(c)

15 The method of Example 1 is repeated, except that
a combination of botulinum toxin type A and D is used
with similar results.

Example 1(d)

20 The method of Example 1 is repeated, except that
a combination of botulinum toxin type A and E is used
with similar results.

25

Example 1(e)

30 The method of Example 1 is repeated, except that
a combination of botulinum toxin type A and F is used
with similar results.

Example 1(f)

5 The method of Example 1 is repeated, except that a combination of botulinum toxin type A and G is used with similar results.

Example 2

Use of Botulinum Toxin in the Treatment
of Spasmodic Torticollis

10

A patient, suffering from spasmodic torticollis, as manifested by spasmodic or tonic contractions of the neck musculature, producing stereotyped abnormal deviations of the head, the chin being rotated to one side, and the shoulder being elevated toward the side at which the head is rotated, is treated by injection with a composition having up to 300 units, or more, of botulinum toxin type A and up to 300 units, or more, of botulinum toxin type E, in the dystonic neck muscles. After a few hours, the symptoms are substantially alleviated; i.e., the patient is able to hold his head and shoulder in a normal position.

15

20

Example 3

Use of Botulinum Toxin in the Treatment
of Essential Tremor

25

30

A patient suffering from essential tremor, which is provoked by maintenance of posture or movement, is treated by injection with therapeutic amounts of botulinum toxin type A and botulinum toxin type B. After two weeks, the symptoms are substantially alleviated.

Example 3(a)

5 The method of Example 3 is repeated except that
a patient suffering from essential tremor is injected
with botulinum toxin type A and C. A similar result
is obtained.

Example 3(b)

10 The method of Example 3 is repeated, except that
a patient suffering from essential tremor is injected
with botulinum toxin type A and D. A similar result
is obtained.

15 Example 3(c)

20 The method of Example 3 is repeated, except that
a patient suffering from essential tremor is injected
with botulinum toxin type A and E. A similar result
is obtained.

Example 3(d)

25 The method of Example 3 is repeated, except that
a patient suffering from essential tremor is injected
with botulinum toxin type A and F. A similar result
is obtained.

Example 3(e)

30 The method of Example 3 is repeated, except that
a patient suffering from essential tremor is injected
with botulinum toxin type A and G. A similar result
is obtained.

35

Example 4

Use of Botulinum Toxin in the Treatment
of Spasmodic Dysphonia

5 A patient, unable to speak clearly due to spasm
of the vocal chords, is treated by injection of
therapeutic amounts of botulinum toxin type A and
therapeutic amounts of botulinum toxin type B. After
a few hours, the patient is able to speak clearly.

10

Example 4(a)

 The method of Example 4 is repeated except that
a patient suffering from spasmodic dysphonia is
15 injected with botulinum toxin type A and C. A similar
result is obtained.

Example 4(b)

20 The method of Example 4 is repeated, except that
a patient suffering from spasmodic dysphonia is
injected with botulinum toxin type A and D. A similar
result is obtained.

25

Example 4(c)

 The method of Example 4 is repeated, except that
a patient suffering from spasmodic dysphonia is
injected with botulinum toxin type A and E. A similar
30 result is obtained.

Example 4(d)

35 The method of Example 4 is repeated, except that
a patient suffering from spasmodic dysphonia is

injected with botulinum toxin type A and F. A similar result is obtained.

Example 4(e)

5

The method of Example 4 is repeated, except that a patient suffering from spasmodic dysphonia is injected with botulinum toxin type A and G. A similar result is obtained.

10

Example 5

Use of Botulinum Toxin in the Treatment
of Hemifacial Spasm

15

A patient is suffering from hemifacial spasm as manifested by involuntary rapid synchronous contraction of muscles innervated by the facial nerve on one side. The symptoms are sufficiently advanced to show not only contraction of the muscles around the eye, but twitches spread to involve the other ipsilateral facial muscles. The patient is injected with up to 300 units of botulinum toxin type A and up to 300 units of botulinum toxin type B, and after a few hours, the symptoms are substantially alleviated.

25

Example 5(a)

30

The method of Example 5 is repeated except that a patient suffering from hemifacial spasm is injected with botulinum toxin type A and C. A similar result is obtained.

Example 5(b)

5 The method of Example 5 is repeated, except that
a patient suffering from hemifacial spasm is injected
with botulinum toxin type A and D. A similar result
is obtained.

Example 5(c)

10 The method of Example 5 is repeated, except that
a patient suffering from hemifacial spasm is injected
with botulinum toxin type A and E. A similar result
is obtained.

15 Example 5(d)

20 The method of Example 5 is repeated, except that
a patient suffering from hemifacial spasm is injected
with botulinum toxin type A and F. A similar result
is obtained.

Example 5(e)

25 The method of Example 5 is repeated, except that
a patient suffering from hemifacial spasm is injected
with botulinum toxin type A and G. A similar result
is obtained.

Example 6

30 Use of Botulinum Toxin in the Treatment
of Blepharospasm

35 A 60-year old woman suffering from idiopathic
blepharospasm, a focal form of dystonia involving the
orbicularis oculi muscles and producing involuntary

eye closure, is treated by injection with a therapeutic amount of botulinum toxin type A and type B into the orbicularis oculi muscle. A total of eight injections, both laterally and medially at the junction of the orbital and preseptal orbicularis is made. Twice as much of the solution is injected laterally as medially. Within twelve to twenty-four hours, detectable muscle weakness begins. Clinical improvement shows in two to three days. The involuntary blinking ceases. The effect of the injections lasts for 75 days.

Example 6(a)

The method of Example 6 is repeated except that a patient suffering from idiopathic blepharospasm is injected with botulinum toxin type A and C. A similar result is obtained.

Example 6(b)

The method of Example 6 is repeated, except that a patient suffering from idiopathic blepharospasm is injected with botulinum toxin type A and D. A similar result is obtained.

Example 6(c)

The method of Example 6 is repeated, except that a patient suffering from idiopathic blepharospasm is injected with botulinum toxin type A and E. A similar result is obtained.

Example 6(d)

5 The method of Example 6 is repeated, except that
a patient suffering from idiopathic blepharospasm is
injected with botulinum toxin type A and F. A similar
result is obtained.

Example 6(e)

10 The method of Example 6 is repeated, except that
a patient suffering from idiopathic blepharospasm is
injected with botulinum toxin type A and G. A similar
result is obtained.

15 Although there has been hereinabove described a
use of multiple botulinum toxins for treating
neuromuscular disorders and conditions in accordance
with the present invention, for the purpose of
illustrating the manner in which the invention may be
20 used to advantage, it should be appreciated that the
invention is not limited thereto since many obvious
modifications can be made, and it is intended to
include within this invention any such modifications
as will fall within the scope of the appended claims.
25 Accordingly, any and all modifications, variations, or
equivalent arrangements which may occur to those
skilled in the art, should be considered to be within
the scope of the present invention as defined in the
appended claims.

30